Health and Biotech - Brand South Africa

Health and biotech

This is where African healthcare innovation scales

South Africa operates the continent’s most advanced healthcare and life sciences ecosystem—producing 40% of Africa’s pharmaceuticals, conducting clinical trials for global biopharma, and exporting medical devices to 100+ countries.

With regulatory alignment to FDA and EMA standards, accredited research institutions, and a pipeline of biotech startups in gene therapy and diagnostics, South Africa offers life sciences investors the infrastructure, talent, and regulatory clarity to build for African and global markets.

From API production and biosimilars to AI-driven diagnostics and mobile health platforms, this is where African healthcare innovation scales.With 5G coverage in major metros, fiber connectivity reaching 12+ million premises, and government digital transformation initiatives underway, South Africa offers investors the infrastructure to build, test, and scale technology solutions across a 1.4 billion-person AfCFTA market.

Health and biotech

Success Stories

Major players—Aspen Pharmacare, Adcock Ingram, Biovac—manufacture here. And new investment is accelerating: vaccine production facilities, clinical research organizations, medical device manufacturing, and telemedicine platforms scaling across the continent.

Clinical Trials and R&D Hub

50+ clinical trials since 2018

US$200M+ invested

Hundreds of scientists trained

Novartis (Switzerland): Clinical Trials & R&D Hub

Novartis has designated South Africa as its lead African base for clinical research, particularly in oncology and generics. Between 2018 and 2024, the firm sponsored 50+ clinical trials in Cape Town and Johannesburg, investing more than US$200 million into contract research organisations (CROs) and trial infrastructure. Hundreds of scientists and clinical staff have been trained under global protocols, embedding advanced R&D standards locally. South Africa’s diverse patient base, strong regulatory oversight (SAHPRA), and hospital networks make it the preferred trial destination on the continent.

Novartis Africa health reports | ClinicalTrials.gov South Africa registry | Engineering News

Diagnostics & Devices Expansion

Expanded distribution hubs

Diagnostics + injection devices supplied

Regional logistics role

Becton Dickinson (USA): Diagnostics & Devices Expansion

Becton Dickinson (BD), a leading US medical technology company, has expanded its South African footprint through investments in diagnostics equipment, injection devices, and training programmes for local health providers. With new warehousing and distribution hubs in Johannesburg, BD supplies molecular diagnostic platforms and devices to hospitals across Southern Africa. The investment strengthens health system resilience, reduces reliance on imports, and anchors South Africa as BD’s logistics and training hub for the SADC region.

BD Africa announcements | HealthTech Africa reports

Cape Town mRNA Facility

US$50M investment

200 skilled jobs

500M doses annual design capacity

Moderna (USA): Cape Town mRNA Facility — Coming Soon

Moderna broke ground in late 2023 on a US$50M mRNA facility at Biovac’s Cape Town campus, marking its first African production site. As of mid-2025, construction is ~60% complete, with equipment installation planned for Q1 2026 and operations targeted for late 2025 pending SAHPRA approval. Designed for up to 500 million doses annually, the facility will employ ~200 skilled workers and support African Union targets of 60% local vaccine production by 2040. This “coming soon” pipeline project underscores multinational confidence in South Africa’s regulatory and scientific ecosystem.

Moderna press release (2023–2025) | Biovac construction updates

Africa’s First mRNA Tech Transfer

100M+ annual dose capacity

First mRNA transfer in Africa

WHO & Pfizer backing

Pfizer/BioNTech (USA/Germany) + Biovac (SA): Africa’s First mRNA Tech Transfer

In 2021, Pfizer/BioNTech selected Biovac in Cape Town for Africa’s first mRNA technology transfer, supported by the WHO’s global mRNA hub. The investment elevated Biovac’s capabilities to produce over 100 million doses annually through fill-and-finish operations meeting strict GMP standards. Beyond COVID-19, Biovac is now positioned to adapt this platform for other vaccines and biologics, embedding sovereign production capacity. The move built local scientific skills, created jobs, and integrated South Africa more deeply into global vaccine supply chains.

Pfizer/BioNTech press release (2021) | WHO mRNA Hub statements

Africa’s Vaccine Manufacturing Hub

300M+ doses produced

|Africa’s largest sterile platform

Global export contracts

Johnson & Johnson (USA) + Aspen Pharmacare (SA): Africa’s Vaccine Manufacturing Hub

Johnson & Johnson partnered with Aspen Pharmacare in Gqeberha to establish Africa’s largest sterile pharmaceutical facility, enabling local fill-and-finish production of COVID-19 vaccines and beyond. At peak, Aspen produced more than 300 million J&J doses, supplying both African and global markets. The partnership embedded critical tech transfer, QA protocols, and workforce training, proving South Africa’s capacity to manufacture biologics at global scale. This inward investment secured jobs, strengthened supply resilience, and demonstrated South Africa’s role in global pharma security.

Johnson & Johnson/Aspen releases (2021–2023) | Financial Times | Business Day

Rift Valley Fever mRNA Vaccine R&D Grant

CEPI-funded

mRNA platform

Emerging-threat focus

Skills uplift

STATUS:

Pipeline (R&D funded; pre-clinical stage)

Afrigen + CEPI: Rift Valley Fever (RVF) mRNA Vaccine R&D Grant

Afrigen Biologics & Vaccines secured a grant from CEPI to develop a first-in-class mRNA vaccine against Rift Valley fever, leveraging SA’s growing mRNA ecosystem. The programme builds on Afrigen’s WHO-linked technology transfer work and strengthens local scientific capacity across discovery, process development and pre-clinical validation. If successful, RVF mRNA could de-risk animal-human transmission in Africa and open pathways to other emerging threats — a strong health sovereignty signal for SA and the AU.

CEPI press centre | Afrigen announcements

Cape Town Biotech & Diagnostics Site

New hub operational

| Diagnostics + cold-chain + training

Regional distribution role

STATUS:

Operational (site opened; ramp-up in progress)

Roche Diagnostics: Cape Town Biotech & Diagnostics Site

Roche has opened a new biotech/diagnostics facility in Cape Town (Brackengate 2), expanding local capability in sample prep, cold-chain distribution and clinical lab support. The site is configured for high-throughput diagnostics and training, improving speed-to-care for public and private providers while anchoring regional supply reliability. Roche expects material job creation over the first three years with deeper localisation of service and support. The investment signals long-term confidence in South Africa as a diagnostics and medical device hub for SADC.

Roche press room | Local business park | Western Cape investment updates

Health and biotech

What the world says

From investors to industry leaders, each testimony offers an outside view of the country’s reform momentum, economic resilience, and growing global influence. Together, they reveal how South Africa is shaping — and being shaped by — the future of investment, innovation, and partnership.

PwC Strategy& — SA Outlook (Jan 2025)

“South Africa’s macroeconomic outlook at the start of 2025 is notably better… much more to be positive about than 12 months ago.”

Context / Impact:
PwC cites lower inflation, easing interest rates, and improved sentiment following the GNU. Forecasts GDP growth of 0.5–1.3%.

Why it matters for investors:
Confirms improving cycle—supportive rates and sentiment reduce hurdle rates for projects.

Source: PwC South Africa Economic Outlook 2025

IMF — Article IV Consultation (Jan 2025)

“Directors welcomed South Africa’s new Government of National Unity… The fresh mandate offers an historic opportunity to pursue ambitious reforms.”

Context / Impact:
The IMF projects GDP growth to accelerate to 1.5% in 2025 (from 0.9% in 2024), supported by stabilised electricity supply, reform momentum, and improving confidence.

Why it matters for investors:
Signals macro stability and a reform runway—improving risk-adjusted returns and policy predictability.

Source: IMF Article IV Summary 2025

Health and biotech